Antipsychotic use bymedicaid-insured youths: Impact of eligibility and psychiatric diagnosis across a decade

Psychiatric Services

Volumn 64, Issue 3, 2013, Pages 223-229

  Zito, Julie Magno ^a   Burcu, Mehmet ^a   Ibe, Aloysius ^c   Safer, Daniel J ^d   Magder, Laurence S ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MORGAN STATE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADJUSTMENT DISORDER; ADOLESCENT; AFRICAN AMERICAN; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; COMMUNICATION DISORDER; CROSS-SECTIONAL STUDY; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG USE; FEMALE; FOSTER CARE; HEALTH INSURANCE ELIGIBILITY; HISPANIC; HUMAN; INCOME; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DEFICIENCY; MENTAL DISEASE; PRESCHOOL CHILD; PREVALENCE; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; SCHOOL CHILD; UNITED STATES; CLINICAL PRACTICE; ORGANIZATION AND MANAGEMENT;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; MALE; MEDICAID; MENTAL DISORDERS; MID-ATLANTIC REGION; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 84882311159     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200081     Document Type: Article

References (21)

1. Domino ME, Swartz MS: Who are the new users of antipsychotic medications? Psychiatric Services 59:507-514, 2008
2. Zito JM, Safer DJ, DosReis S, et al: Psychotropic practice patterns for youth: A tenyear perspective. Archives of Pediatrics and Adolescent Medicine 157:17-25, 2003
3. Crystal S, Olfson M, Huang C, et al: Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs 28:w770-w781, 2009
4. Olfson M, Blanco C, Liu L, et al: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 63: 679-685, 2006
5. Patel NC, Crismon ML, Hoagwood K, et al: Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 44:548-556, 2005
6. Pathak P, West D, Martin BC, et al: Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatric Services 61:123-129, 2010
7. Zito JM, Safer DJ, Zuckerman IH, et al: Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatric Services 56:157-163, 2005
8. Olfson M, Crystal S, Huang C, et al: Trends in antipsychotic drug use by very young, privately insured children. Journal of the American Academy of Child and Adolescent Psychiatry 49:13-23, 2010
9. Constantine RJ, Tandon R, McPherson M, et al: Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's Medicaid program. Journal of Child and Adolescent Psychopharmacology 21:79-84, 2011
10. Calarge CA, Acion L, Kuperman S, et al: Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. Journal of Child and Adolescent Psychopharmacology 19: 101-109, 2009
11. Correll CU, Manu P, Olshanskiy V, et al: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009
12. Safer DJ: A comparison of risperidoneinduced weight gain across the age span. Journal of Clinical Psychopharmacology 24:429-436, 2004
13. Medicaid.gov: Keeping America Healthy. Baltimore, Centers for Medicare and Medicaid Services. Available at www.medicaid.gov/Medicaid-CHIP-Program- Information/By-Population/By-population. html. Accessed Dec 23, 2011
14. Curtis LH, Masselink LE, Østbye T, et al: Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Archives of Pediatrics and Adolescent Medicine 159:362-366, 2005
15. Zito JM, Safer DJ, dosReis S, et al: Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283: 1025-1030, 2000
16. Carlson GA, Blader JC: Diagnostic implications of informant disagreement for manic symptoms. Journal of Child and Adolescent Psychopharmacology 21:399-405, 2011
17. Geller B, Warner K, Williams M, et al: Prepubertal and young adolescent bipolarity versus ADHD: Assessment and validity using the WASH-U-KSADS, CBCL and TRF. Journal of Affective Disorders 51:93-100, 1998
18. Youngstrom E, Youngstrom JK, Starr M: Bipolar diagnoses in community mental health: Achenbach Child Behavior Checklist profiles and patterns of comorbidity. Biological Psychiatry 58:569-575, 2005
19. Olfson M, Crystal S, Gerhard T, et al: Mental health treatment received by youths in the year before and after a new diagnosis of bipolar disorder. Psychiatric Services 60:1098-1106, 2009
20. Leibenluft E: Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. American Journal of Psychiatry 168:129-142, 2011
21. Pappadopulos E, Woolston S, Chait A, et al: Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. Journal of the Canadian Academy of Child and Adolescent Psychiatry 15: 27-39, 2006